This $599,921 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to examine the role of the gene METTL3 in the cardiac benefits of exercise for individuals with diabetes. The award recipient, The General Hospital Corporation (Massachusetts General Hospital), will conduct studies to determine if METTL3 is necessary and sufficient for the beneficial cardiac effects of exercise in diabetes, as well as investigate the mechanisms by which METTL3 regulates diabetic cardiomyopathy. The research aims to shed new light on the role of RNA modification in the pathophysiology of diabetic cardiomyopathy and establish clinically relevant approaches targeting METTL3 to combat this complication in diabetes patients. The project is expected to run from July 2024 to June 2029.
Generated 1/28/25, 7:16 AM